Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lemaitre Vascular (LMAT) Asset Writedowns and Impairment (2016 - 2025)

Lemaitre Vascular (LMAT) has disclosed Asset Writedowns and Impairment for 16 consecutive years, with $2.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Asset Writedowns and Impairment rose 269.56% to $2.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.7 million, a 227.31% increase, with the full-year FY2025 number at $2.7 million, up 227.31% from a year prior.
  • Asset Writedowns and Impairment was $2.2 million for Q4 2025 at Lemaitre Vascular, up from -$575000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $2.2 million in Q4 2025 to a low of -$2.8 million in Q4 2021.
  • A 5-year average of $330550.0 and a median of $363500.0 in 2023 define the central range for Asset Writedowns and Impairment.
  • Peak YoY movement for Asset Writedowns and Impairment: soared 2227.78% in 2021, then crashed 545.68% in 2023.
  • Lemaitre Vascular's Asset Writedowns and Impairment stood at -$2.8 million in 2021, then soared by 48.31% to -$1.4 million in 2022, then skyrocketed by 252.99% to $2.2 million in 2023, then crashed by 159.76% to -$1.3 million in 2024, then surged by 269.56% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for LMAT's Asset Writedowns and Impairment are $2.2 million (Q4 2025), -$575000.0 (Q3 2025), and $393000.0 (Q2 2025).